David R. Wise, Tian Zhang, Biren Saraiya, Jose W. Avitia, Andrew J. Armstrong, Shuchi Gulati, Manojkumar Bupathi, Alexandra Sokolova, Ronald Tutrone, Svetlana Shpyro, Olga Blokhina, Qiong Wang, Yang Liu, Joan Durbin, Pan Zheng, Mark N. Stein. "Updated efficacy results from the phase 1 study of gotistobart (BNT316/ONC-392) in combination with lutetium Lu 177 vipivotide tetraxetan (Lu 177) in patients with metastatic castration-resistant prostate cancer (mCRPC).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.7_suppl.175